Core Viewpoint - Immunome, Inc. reported a quarterly loss of $0.52 per share, which was better than the Zacks Consensus Estimate of a loss of $0.66, indicating a positive earnings surprise of 21.21% [1] Financial Performance - The company posted revenues of $2.93 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 28.33%, compared to revenues of $1.03 million in the same quarter last year [2] - Over the last four quarters, Immunome has only surpassed consensus EPS estimates once [2] Stock Performance - Immunome shares have declined approximately 29.8% since the beginning of the year, while the S&P 500 has only declined by 3.8% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.66 on revenues of $2.28 million, and for the current fiscal year, it is -$2.69 on revenues of $9.13 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Immunome belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

美国加州理工学院研究团队近日在医学3D打印领域取得突破性进展。他们开发出一种可在体内直接制 造医疗植入物和定制化治疗组织的新技术，无需进行传统侵入性手术。该技术为未来精准医疗开辟了新 方向。成果发表于最新一期《科学》杂志。 此外，该技术所使用的生物墨水具有高度可调性。人们可根据需要设计其性能，如增强导电性、实现药 物缓释、促进组织黏附，甚至具备实时成像功能，为多种疾病的治疗提供灵活方案。 这项新技术被称为"成像引导深层组织体内超声打印"（DISP），它结合了聚焦超声与特制的"超声墨 水"，能够在身体深处精准制造生物材料。研究人员表示，这一技术有望彻底改变个性化医疗的方式， 为疾病治疗提供更安全、更精准的解决方案。 在实验中，团队成功在小鼠的膀胱肿瘤附近和兔子的深层肌肉组织中，打印出了有载药的功能性生物材 料，验证了DISP在药物输送、组织修复和生物电子器件构建中的应用潜力。安全评估显示，该技术未 引发明显炎症或组织损伤，且凝胶墨水不会在一周内被机体自然清除，有良好的生物相容性。 目前，3D生物打印技术已在医学界展现出巨大潜力。但打印个性化植入物时，大多数现有方法仍需通 过手术将打印材料植入体内，存在创伤大、风 ...

1.【小鹏汇天"陆地航母"飞行体生产许可证（PC）申请获受理】小鹏汇天5月9日宣布，"陆地航母"飞行体 （代号：X3-F）生产许可证（PC）申请正式获得民用航空中南地区管理局受理，标志着飞行汽车产品量 产体系开始接受局方审查。（财联社） 2.【古尔曼：苹果正为新Mac、智能眼镜和AI服务器开发专用芯片】根据彭博社马克·古尔曼的说法，苹果 正在开发一款专为智能眼镜设计的新型芯片，目标在2026至2027年实现量产，计划未来两年左右推出对 应的智能眼镜产品，与Meta旗下Ray-Ban直接竞争。（搜狐） 3.【纳米3D打印磷酸钙：陶瓷骨移植的新未来】在悉尼大学，由生物医学工程教授兼创新生物工程培训 中心主任Hala Zreiqat领导的研究人员开发了一种3D打印方法，用于制造纳米结构的磷酸钙。（搜狐） 4.【我国首艘深水铺管起重船进入国际市场】驻津央企海洋石油工程股份有限公司旗下的我国首艘深水铺 管起重船——"海洋石油201"船启航，驶向中东区域海管作业现场。这也是该船首次进入国际市场，对提 升我国大型海洋工程船舶国际化运营能力具有重要意义。 "海洋石油 201"船是世界上第一艘同时具备4000吨级重型起重能力、 ...

CG Oncology, Inc. (CGON) shares ended the last trading session 25% higher at $27.97. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 15.3% loss over the past four weeks.CG Oncology’s shares jumped 25% on Monday after the company unveiled exceptionally durable best-in-disease phase III data for its bladder cancer candidate, cretostimogene grenadenorepvec, at the American Urological Association meeting. In the BOND-0 ...

A month has gone by since the last earnings report for Editas Medicine (EDIT) . Shares have lost about 37.1% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Editas due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.How Have Estimates Been Moving Since Then?It turns ...